» Articles » PMID: 26742516

Impaired Neurovisceral Integration of Cardiovascular Modulation Contributes to Multiple Sclerosis Morbidities

Overview
Journal Mol Neurobiol
Date 2016 Jan 9
PMID 26742516
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease with an uncertain etiology. MS is heterogeneous, involving multiple clinical pathologies, including neurodegeneration, depression, fatigue and sleep disorders, migraine, osteoporosis and cerebral hemodynamic impairments. The underlying causes of these pathologies remain mostly unknown. Based on the accumulating evidence derived from our studies and those of other investigators, we propose that the dysregulation in the neurovisceral integration of cardiovascular modulation can lead to many MS-related clinical symptoms. We show that MS inflammatory and neurodegenerative processes are intertwined with the aforementioned clinical morbidities and are collectively the manifestations of cardiovascular autonomic nervous system (ANS) dysfunction. The strategies for improving sympathovagal balance would likely prevent and minimize many MS-related clinical symptoms, improving patients' quality of life. Similar strategies could be applied to other autoimmune and neurodegenerative diseases where autonomic imbalance plays a role.

Citing Articles

Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis.

Kontaxis S, Laporta E, Garcia E, Guerrero A, Zabalza A, Matteo M Front Physiol. 2023; 14:1145818.

PMID: 37089424 PMC: 10117218. DOI: 10.3389/fphys.2023.1145818.


Cardiovascular Autonomic Dysfunction and Falls in People With Multiple Sclerosis: Is There a Link? An Opinion Article.

Zanotto T, Hernandez M, Medrano C, Wilund K, Sosnoff J Front Neurosci. 2020; 14:610917.

PMID: 33364920 PMC: 7750464. DOI: 10.3389/fnins.2020.610917.


Cardiac Autonomic Modulation Is Different in Terms of Clinical Variant of Multiple Sclerosis.

Zawadka-Kunikowska M, Rzepinski L, Newton J, Zalewski P, Slomko J J Clin Med. 2020; 9(10).

PMID: 33008032 PMC: 7601922. DOI: 10.3390/jcm9103176.


Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigue.

Krbot Skoric M, Crnosija L, Adamec I, Barun B, Gabelic T, Smoljo T Clin Auton Res. 2018; 29(3):321-328.

PMID: 30209702 DOI: 10.1007/s10286-018-0563-6.


Sympathetic cardiovascular and sudomotor functions are frequently affected in early multiple sclerosis.

Habek M, Crnosija L, Lovric M, Junakovic A, Krbot Skoric M, Adamec I Clin Auton Res. 2016; 26(6):385-393.

PMID: 27448576 DOI: 10.1007/s10286-016-0370-x.

References
1.
Whedon J, Glassey D . Cerebrospinal fluid stasis and its clinical significance. Altern Ther Health Med. 2009; 15(3):54-60. PMC: 2842089. View

2.
Burrell A, Handel A, Ramagopalan S, Ebers G, Morahan J . Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC). Discov Med. 2011; 11(58):187-96. View

3.
Panitch H, Miller A, Paty D, Weinshenker B . Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004; 63(10):1788-95. DOI: 10.1212/01.wnl.0000146958.77317.3e. View

4.
Villoslada P, Oksenberg J, Rio J, Montalban X . Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2004; 62(9):1653. DOI: 10.1212/wnl.62.9.1653. View

5.
Khoury S, Healy B, Kivisakk P, Viglietta V, Egorova S, Guttmann C . A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010; 67(9):1055-61. PMC: 2954052. DOI: 10.1001/archneurol.2010.222. View